Dear Editor,

We appreciate Drs. Tamura and Satoh’s interest in our work and the opportunity they give us to respond to their four questions.

Firstly, as mentioned in the section methods of our study “… participants were selected based on age and self-reporting of ‘a doctor’s diagnosis’ of respiratory disease (ICD-10-CM diagnosis codes J00-J99). Individuals using inhalers (short or long acting β2 adrenergic and/or anticholinergics and/or corticosteroids) without ever having reported in the questionnaires ‘a doctor’s diagnosis’ of respiratory disease were also included as having ‘possible obstructive pulmonary disease’. Finally, among participants, those reporting chronic obstructive pulmonary disease (J44), asthma (J45) and emphysema (J43) were identified in order to perform additional subgroup analyses” [1]. Also, in Table 1 we present separately the characteristics of participants reporting a respiratory disease with ICD-10-CM diagnosis code J44, J45, J43 as well as those having “possible obstructive pulmonary disease”. Finally, among participants, those reporting chronic obstructive pulmonary disease (J44), asthma (J45) and emphysema (J43) were identified in order to perform additional subgroup analyses” [1]. Also, in Table 1 we present separately the characteristics of participants reporting a respiratory disease with ICD-10-CM diagnosis code J44, J45, J43 as well as those having “possible obstructive pulmonary disease”. Finally, among participants, those reporting chronic obstructive pulmonary disease (J44), asthma (J45) and emphysema (J43) were identified in order to perform additional subgroup analyses” [1]. Also, in Table 1 we present separately the characteristics of participants reporting a respiratory disease with ICD-10-CM diagnosis code J44, J45, J43 as well as those having “possible obstructive pulmonary disease” (see above for definition). The category “others” refer to those reporting any other ICD-10-CM diagnosis code from J00-J99.

Secondly, in the EPIC-Greece study no information has been collected so far on the reasons a specific medication is prescribed by doctors for any disease, COPD included.

Thirdly, due to the study design no data are available on the administration period of steroids.

References:


Address for correspondence: Hiroaki Satoh, MD, Division of Respiratory Medicine, Mito Medical Center, University of Tsukuba, Miyashita-cho 3-2-7, Mito, Ibaraki, 310-0015, Japan. Tel: +81-29-231-2371, Fax: +81-29-221-5137, e-mail: hirosato@md.tsukuba.ac.jp

DOI: 10.5603/ARM.2017.0020
Received: 14.03.2017
Copyright © 2017 PTChP
ISSN 2451–4834
Fourthly, probably there is a misunderstanding because we did not draw such a conclusion in our study. Comparing the risk of hip fracture between participants treated with inhaled steroids versus those taking oral steroids was not among the objectives of the current study. Other studies, specifically designed, should further address this issue.

Conflict of interest

The authors declare no conflict of interest.

References: